The launch of new liquid biopsy products and expanding test offerings position the company to capture market share and benefit from growth in oncology diagnostics demand. 2026 guidance anticipates continued revenue and margin expansion, supported by new product adoption and operational efficiencies, though the company currently operates at a loss as it invests in growth.
Cyborg Score Rationale
NeoGenomics shows solid revenue growth (10.6% YoY), recent earnings beat expectations, and a strengthening balance sheet, but faces profitability challenges with negative margins and uncertain near-term earnings outlook. Analyst sentiment is mixed with a "Hold" consensus.
Top Insights
Q4 2025 EPS beat estimates ($0.06 vs $0.04) with revenue of $190.17M, representing 10.6% YoY growth
Market cap of $1.28B with negative PE ratio (-11.70), reflecting current unprofitability
Federal court invalidated Natera's patent claims, freeing NEO to commercialize its RaDaR ST cancer test, potentially unlocking massive growth
Analyst split with 8 Hold, 5 Buy, and 1 Sell rating reflecting cautious optimism
Named Competitors
Diagnostic Services — Large diversified clinical laboratory company
Pathology Services — Regional pathology and laboratory services
Oncology Diagnostics — Cancer diagnostic testing company
Recent Developments
(February 2026) Q4 2025 earnings beat with $0.06 EPS and revenue of $190.17M, up 10.6% YoY
(February 2026) Needham raised price target to $15.00 with Buy rating; Piper Sandler raised to $13.00
(Recent) Federal court invalidated competitor Natera's patent claims, clearing path for RaDaR ST commercialization
Open the full interactive NeoGenomics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.